Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
1. Lexicon submitted new data for Zynquista NDA resubmission. 2. FDA to provide feedback by end of September 2025. 3. Patient support for Zynquista's approval remains high. 4. Concerns over ketoacidosis led to previous FDA response. 5. Lexicon focuses on obtaining regulatory approval for Zynquista.